A Study of Tor Kinase Inhibitor in Advanced Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.

Key facts

Study ID: NCT00731263
Run by: AstraZeneca
People needed: 64
Starts: 2008-07-01
Expected to finish: 2010-11-01
Last updated by the study team: 2012-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histological or cytological confirmation of an advanced solid malignant tumour (or lymphoma Part A only)
Cancer which is refractory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria) can be recruited to Part A
Evidence of post-menopausal status or negative urine/serum pregnancy test for pre-menopausal female patients

You may not qualify if…

Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug.
Patients with abnormal fasting glucose, have type I or II Diabetes or have uncontrolled blood fats and cholesterol
Patients with a history of neurological disease, peripheral or central neuropathy, brain metastases or family history of myopathy are excluded
Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions

Where it is running

Research Site — New York, New York, United States
Research Site — Houston, Texas, United States
Research Site — Clichy, France
Research Site — Sutton, Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.